Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Shares Shorted: Short Interest Down 53.4% in September

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 9,250 shares, a drop of 53.4% from the September 15th total of 19,861 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 6,232 shares, the short-interest ratio is presently 1.5 days.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on AAPG shares. JPMorgan Chase & Co. dropped their price target on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday, October 8th. BTIG Research reiterated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Citigroup assumed coverage on Ascentage Pharma Group International in a research note on Tuesday. They issued an “outperform” rating for the company. Finally, Citizens Jmp began coverage on Ascentage Pharma Group International in a report on Tuesday. They set a “market outperform” rating and a $35.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $43.67.

Ascentage Pharma Group International Stock Performance

AAPG opened at $15.06 on Wednesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The company’s fifty day moving average price is $16.65 and its two-hundred day moving average price is $19.22. Ascentage Pharma Group International has a 1-year low of $14.45 and a 1-year high of $37.50.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million for the quarter. As a group, equities research analysts expect that Ascentage Pharma Group International will post -2.42 earnings per share for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.